$9.720
-0.148 (-1.52%)Zum Schluss
TRIB-News
TRIB-Events
Trinity Biotech Adjusts ADS Ratio to 1:600
Trinity Biotech announced that it plans to change the ratio of the American depositary shares representing its Class A ordinary shares from one ADS representing 20 Class A ordinary shares to one ADS representing 600 Class A ordinary shares. For Trinity Biotech ADS holders, the change in the ADS ratio will have the same effect as a one for-thirty reverse ADS split and is intended to enable the company to regain compliance with the $1.00 Nasdaq minimum bid price requirement, and facilitate investment from a broader pool of potential investors, who may have previously been unable to invest due to the ADSs trading below a price of $5.00.
Trinity Biotech Signs Strategic Collaboration Agreement with Latch Medical
Trinity Biotech announced a strategic collaboration agreement with Latch Medical. The collaboration is intended to combine data streams from Trinity Biotech's CGM+ wearable biosensor platform with Latch Medical's advanced drug delivery technologies to evaluate the development of precision therapeutic solutions for diabetes, obesity and other metabolic conditions. The companies will explore how real-time metabolic data generated by CGM+ can be used to help guide and optimize therapeutic delivery, creating the potential for more personalized and responsive treatment approaches. As part of the collaboration, Trinity Biotech has also agreed in principle to make a strategic equity investment in Latch Medical, which has previously attracted strategic investment from established participants in the global drug delivery industry. Trinity Biotech's planned investment reflects its belief in the potential importance of precision intradermal delivery technologies within next-generation metabolic health solutions.
Trinity Biotech Officially Terminates Equity Purchase Agreement with Yorkville
Trinity Biotech announced that it has formally provided notice of termination to YA II PN, an affiliate of financing partner Yorkville Advisors Global, in respect of its standby equity purchase agreement, or SEPA, for an equity line of credit facility. The company has determined that it does not intend to make any further use of the SEPA. Accordingly, termination of the equity line of credit facility reflects the company's current financing strategy.
Trinity Biotech Secures Over 2M Orders for HIV Rapid Test
Trinity Biotech announced that it has received additional purchase orders for over 2M units of its rapid HIV test, TrinScreen HIV. These orders are scheduled for fulfillment in Q3 and are expected to make a meaningful contribution to the company's 2026 revenue and profitability objectives.
Trinity Biotech Partners with University at Buffalo to Develop Sjogren's Syndrome Biomarkers
Trinity Biotech announced it has entered into a collaboration agreement with the University at Buffalo, New York, or UB. The partnership focuses on advancing and commercializing a suite of proprietary biomarkers for the earlier and more accurate detection of Sjogren's Syndrome, one of the most common but underdiagnosed autoimmune diseases. Sjogren's Syndrome is a chronic, systemic autoimmune disease that primarily affects moisture producing glands in the eyes and mouth, with potential progressive involvement of multiple organ systems. The disease may affect the nervous system, lungs, and kidneys as well as the function of most other exocrine glands in the human body. Chronic fatigue, joint pain, and neuropathic pain are significant sources of disability. It is widely underdiagnosed and often mistaken for other autoimmune or inflammatory conditions. Under the collaboration agreement Trinity Biotech will codevelop and commercialize proprietary biomarkers discovered by UB faculty researchers and licensed to Trinity Biotech subsidiary IMMCO through Business and Entrepreneur Partnership's Technology Transfer Office, which manages UB's intellectual property and facilitates collaborations between UB faculty researchers and industry partners. Trinity Biotech expects the collaboration to generate multiple downstream benefits, including expanded clinical partnerships, enhanced payer relevant data packages, and a strengthened platform for future biomarker commercialization.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.